Background: There are concerns that Asian patients respond differently to some
medications. This study evaluated the efficacy and safety of evolocumab among Asian vs …

Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …

Background: Evolocumab (AMG 145), a fully human monoclonal antibody inhibiting PCSK9,
significantly reduced LDL-C in phase 2 and 3 studies. This phase 3 study (the largest …

Importance Current guidelines for atherosclerotic cardiovascular disease focus on high-
intensity statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL …

Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …

Background Despite current therapies, patients with vascular disease remain at high risk for
major adverse cardiovascular events. Low-density lipoprotein cholesterol is a well …

Importance The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol
and first cardiovascular events in the Further Cardiovascular Outcomes Research With …

Background: YUKAWA is a 12-week, randomized, double-blind, placebocontrolled, phase 2
study evaluating the efficacy and safety of evolocumab (AMG 145) in statin-treated …

Importance Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive
statin therapy reduces progression of coronary atherosclerosis in proportion to achieved …

Proprotein convertase subtilisin-kexin type 9 (PCSK9) is a protease that binds to the
extracellular compartment of the LDL receptor, hence, targeting the LDL receptor to the …